DnB Asset Management AS Purchases 23,914 Shares of DexCom, Inc. (NASDAQ:DXCM)

DnB Asset Management AS increased its position in DexCom, Inc. (NASDAQ:DXCM) by 10.7% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 246,385 shares of the medical device company’s stock after buying an additional 23,914 shares during the quarter. DnB Asset Management AS owned 0.06% of DexCom worth $19,161,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors and hedge funds have also bought and sold shares of the company. Cerity Partners LLC grew its holdings in shares of DexCom by 190.0% during the 3rd quarter. Cerity Partners LLC now owns 60,050 shares of the medical device company’s stock valued at $4,026,000 after purchasing an additional 39,344 shares during the last quarter. D.A. Davidson & CO. grew its stake in shares of DexCom by 22.4% during the third quarter. D.A. Davidson & CO. now owns 32,578 shares of the medical device company’s stock valued at $2,184,000 after buying an additional 5,969 shares during the last quarter. Townsquare Capital LLC increased its holdings in shares of DexCom by 43.6% in the third quarter. Townsquare Capital LLC now owns 9,568 shares of the medical device company’s stock worth $641,000 after buying an additional 2,905 shares during the period. Freedom Investment Management Inc. lifted its stake in shares of DexCom by 10.2% in the 3rd quarter. Freedom Investment Management Inc. now owns 3,035 shares of the medical device company’s stock valued at $203,000 after acquiring an additional 281 shares during the last quarter. Finally, Healthcare of Ontario Pension Plan Trust Fund boosted its holdings in DexCom by 127.4% during the 3rd quarter. Healthcare of Ontario Pension Plan Trust Fund now owns 83,037 shares of the medical device company’s stock valued at $5,567,000 after acquiring an additional 46,527 shares during the period. 97.75% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of equities analysts have commented on DXCM shares. Cfra Research raised DexCom to a “hold” rating in a research note on Friday, March 21st. Canaccord Genuity Group increased their price target on shares of DexCom from $99.00 to $103.00 and gave the company a “buy” rating in a research report on Friday, February 14th. Robert W. Baird upgraded shares of DexCom from a “neutral” rating to an “outperform” rating and boosted their price objective for the company from $86.00 to $104.00 in a research report on Thursday, January 16th. Citigroup increased their target price on shares of DexCom from $101.00 to $104.00 and gave the stock a “buy” rating in a report on Tuesday, March 4th. Finally, Baird R W upgraded DexCom from a “hold” rating to a “strong-buy” rating in a report on Thursday, January 16th. Five investment analysts have rated the stock with a hold rating, thirteen have given a buy rating and two have issued a strong buy rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $99.82.

Insider Buying and Selling

In other news, EVP Jereme M. Sylvain sold 2,090 shares of the firm’s stock in a transaction on Wednesday, January 29th. The stock was sold at an average price of $86.91, for a total value of $181,641.90. Following the transaction, the executive vice president now directly owns 83,526 shares in the company, valued at $7,259,244.66. This trade represents a 2.44 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, CEO Kevin R. Sayer sold 33,359 shares of the company’s stock in a transaction on Wednesday, January 29th. The shares were sold at an average price of $86.91, for a total value of $2,899,230.69. Following the sale, the chief executive officer now owns 319,037 shares of the company’s stock, valued at approximately $27,727,505.67. This trade represents a 9.47 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 105,009 shares of company stock worth $8,044,178. 0.30% of the stock is owned by insiders.

DexCom Price Performance

Shares of NASDAQ DXCM opened at $67.74 on Friday. The company has a 50 day simple moving average of $82.32 and a two-hundred day simple moving average of $77.01. DexCom, Inc. has a fifty-two week low of $62.34 and a fifty-two week high of $141.99. The company has a market capitalization of $26.47 billion, a price-to-earnings ratio of 47.37, a P/E/G ratio of 2.30 and a beta of 1.28. The company has a debt-to-equity ratio of 0.59, a quick ratio of 1.28 and a current ratio of 1.47.

DexCom (NASDAQ:DXCM) last released its earnings results on Thursday, February 13th. The medical device company reported $0.45 EPS for the quarter, missing the consensus estimate of $0.50 by ($0.05). DexCom had a return on equity of 30.14% and a net margin of 14.29%. Analysts expect that DexCom, Inc. will post 2.03 EPS for the current fiscal year.

DexCom Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.